A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
about
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AEmerging drugs for Guillain-Barré syndromeCorticosteroids for chronic inflammatory demyelinating polyradiculoneuropathyGangliosides for the treatment of diabetic peripheral neuropathyTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsCorticosteroids for chronic inflammatory demyelinating polyradiculoneuropathyImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyTreatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndromeImmunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathyImmunosuppressive treatment for non-systemic vasculitic neuropathyDrug therapy for chronic idiopathic axonal polyneuropathyTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Cerebellar learning distinguishes inflammatory neuropathy with and without tremorComparison of monoclonal gammopathy of undetermined significance-associated neuropathy and chronic inflammatory demyelinating polyneuropathy patientsPostural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjectsClinical outcomes of patients with lumbar disc herniation, selected for one-level open-discectomy and microdiscectomySwitch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.Impairment of small somatic and autonomic nerve fibres in intensive care unit patients with severe sepsis and critical illness polyneuropathy--a single center controlled observational study.Reliability of instrumented movement analysis as outcome measure in Charcot-Marie-Tooth disease: results from a multitask locomotor protocol.Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndromeThe characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational studyAscorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial.Pure sensory chronic inflammatory polyneuropathy: rapid deterioration after steroid treatment.Observer blind randomised controlled trial of a tailored home exercise programme versus usual care in people with stable inflammatory immune mediated neuropathyThe Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy.A randomized trial of diagnostic ultrasound to improve outcomes in focal neuropathies.Value of nerve biopsy in patients with latent malignant hemopathy and peripheral neuropathy: a case series.Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP)Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Drug therapy for chronic idiopathic axonal polyneuropathy.Changes of gait pattern in children with Charcot-Marie-Tooth disease type 1A: a 18 months follow-up study.Outcome measures for Charcot-Marie-Tooth disease: clinical and neurofunctional assessment in children.New advances in the diagnosis and treatment of POEMS syndrome.Progress in peripheral nerve disease research in the last two years.Pain and Physical Functioning in Neuropathic Pain: A Systematic Review of Psychometric Properties of Various Outcome Measures.New insights into the management of chronic inflammatory demyelinating polyradiculoneuropathy.Nine-hole Peg Test and Ten-meter Walk Test for Evaluating Functional Loss in Chinese Charcot-Marie-Tooth DiseaseInternational Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome.Prognostic study for overall survival in patients with newly diagnosed POEMS syndrome.Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome.
P2860
Q22000603-C9CD159C-6F60-422B-A592-7ED8DA2C4515Q22241376-0E76EDA5-70FA-4608-8E18-996C54034848Q24186751-4545C4AD-DAB4-495A-9360-627E970890A1Q24198249-5536B44A-7EF8-467E-878D-014E027D81A5Q24201434-F4DB21D8-0C70-4B84-B6A0-7900B7BFCCFFQ24201662-CF143689-B2D7-497D-8BDD-7C78D5E1264EQ24201954-2C826FEE-4DE6-4857-BDA7-F807EAF5EACFQ24202634-F1C53060-D580-453F-B6DA-F429DC2965D4Q24236599-1106375D-477E-43E4-AF9B-41EC60D37C2EQ24246358-EA115322-D2C6-49B1-ABC2-443344BC38D7Q24247228-20683606-EDA7-4AED-953B-79AEDB2FA3F0Q30397454-7FF0FE75-F138-4FE0-BD84-9DBA3F7D702EQ30443385-AAC28B83-508C-4A74-ACF1-7C9F068570D6Q33990823-685D4296-2F67-484A-80ED-C4D5F5152C86Q34266756-3EE750F1-590D-44F2-B099-01F8F061A812Q34338245-E99A546C-ED92-4B0F-AEFE-C344233F9973Q34457953-E33D7E95-F64D-4078-88DB-6AE9C98804BFQ34493612-223AA102-2D78-4022-BD43-476D9CFB03AEQ35039651-55217FFA-2554-4B95-B96D-48F27DC49878Q35067588-90555FB1-6FD1-4691-AD01-12DE4EB2119CQ35107092-89FDABA6-D937-40FA-B613-8CBDE4704520Q35159258-619DA774-D93E-495A-924D-A37994F7E1BFQ35177035-6445112D-7A99-4A08-8EA6-867EE49A355CQ35751804-EAF2625E-159E-4A56-B8EB-DB4522444E78Q35830457-8DC23671-998F-475D-A692-F3EBCB3AB298Q36132844-01925C77-ABF5-4A31-A1CF-852EE6F5F5F4Q36151870-84608326-85E0-492E-9A93-393DDA20CA25Q36257577-EA0656F7-AAE1-4FF0-94BA-A58EAFAB6913Q36365583-A78BF584-187C-49C7-BE38-13F86806A0D1Q36410068-2CCBEA46-648A-44CF-B6E3-06285A08BC60Q37000938-A27E466F-7CE2-4FEA-8325-29DE6CCCFF24Q37565640-72A28B2B-C487-4B32-8924-49188F233A6AQ38080588-F3407B2F-E5E5-4446-B023-9DD3A3134F70Q38155072-54A6F407-FBDA-4B15-967D-74785EF2C778Q38417354-D7DE466E-DE8C-4E74-9EF4-5C951FAC71B7Q38536776-EDEB0879-D599-4398-B853-D19AF4B42FDFQ38658209-90B9AAAA-6C09-40D4-8945-864E894DA2E4Q38730827-176F4BBB-6F71-494A-8FE0-C6B4A3FC8476Q40684954-DD16324E-DEAF-407E-8EE7-29B6A2FFA521Q41348558-BB52F8B4-61E0-4584-93D9-EDDF75F11D47
P2860
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@ast
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@en
type
label
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@ast
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@en
prefLabel
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@ast
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@en
P2860
P356
P1476
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.
@en
P2093
P2860
P304
P356
10.1136/JNNP.2005.081547
P407
P577
2006-03-30T00:00:00Z